Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hamburg Outlines The Potential Of Regulatory Science Investment

You may also be interested in...



The End Of ‘Regulatory Science’ At US FDA – The Term, Not The Idea

Former Commissioner Margaret Hamburg made advancing regulatory science a centerpiece of her tenure, but it sounds like the term ‘regulatory science’ has outlived its usefulness.

Hamburg’s Departure Hinged On Selection Of FDA Leadership Team

Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.

Hamburg’s Departure Hinged On Selection Of FDA Leadership Team

Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.

Related Content

Topics

UsernamePublicRestriction

Register

PS052698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel